Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit, RedPath Terminate Acquisition Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today announced it is terminating its agreement to buy RedPath Integrated Pathology, following a decision by Medicare to limit its coverage for RedPath's portfolio of tests only to its pancreatic test.

The decision comes after ExonHit and RedPath were unable to agree on revised terms and conditions following the decision by Medicare contractor Highmark Medicare Services to cover only RedPath's TG-Pancreatic cancer test.

ExonHit's deal to purchase RedPath for as much as $32 million was originally announced in the spring, but soon hit a snag when Medicare contractor Highmark Medicare Services announced it intended to drop coverage of RedPath's PathFinder TG-Pancreatic cancer test, pending an assessment of the test.

Last month, after an appeal by RedPath, a personalized diagnostics firm based in Pittsburgh, ExonHit announced Highmark had decided to maintain coverage for the test. Apparently, though, other RedPath tests have been turned down by Highmark for coverage. The firms have not disclosed which tests have been rejected by the Medicare contractor.

In a statement, Paris-based ExonHit said it "maintains its objective to acquire a revenue-generating molecular diagnostic company" as part of its growth strategy.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.